Novatoris launches smartphone-based research into multiple sclerosis

By Laura Mullan
Novatoruis is partnering with Sage Bionetworks to launch a large-scale multiple sclerosis study using data from smartphones. The study, dubbed elevateM...

Novatoruis is partnering with Sage Bionetworks to launch a large-scale multiple sclerosis study using data from smartphones.

The study, dubbed elevateMS, hopes to evaluate, in real time, the daily struggles faced by people living with MS.

The study will use an app to collect information about patient’s movement performance and symptoms from their smartphones.

RELATED STORIES:

It is hoped that the results may help researchers develop new ways to measure treatment’s effectiveness.

Designed with input from patients, neurologists and disease advocates, the study’s mobile app was built on the Apple ResearchKit platform.

Beneficially, the mobile format eliminates the need for clinic visits which broadens the population that can participate. It’s an outcome that is already pushing some oncology companies to search for digital solutions of their own as fewer potential trial participants emerge.

In a statement, Dr Stanley Cohan, medical director of the Providence Multiple Sclerosis Centre in Oregon said: “As physicians, we always want to know how our patients with MS are doing on the treatments we prescribe.

“With the elevateMS app, study participants can frequently document their symptoms in a personal health story.

“In turn, this data may provide researchers with new ways to look at disease progression and treatment effectiveness.”

The study is entitled “Evaluation of Evidence from Smart Phone Sensors and Patient-Reported Outcomes in Participants with Multiple Sclerosis (elevateMS)

Share

Featured Articles

Comarch Diagnostic Point Boost for European Health Insurance

Healthtech specialist Comarch introduces Diagnostic Point, designed to improve health insurance across European markets

McKinsey: Women More Likely to die of Heart Attack Than Men

McKinsey Health Institute's Lucy Pérez says cardiovascular disease top killer of women yet physicians don't know their heart attack symptoms are different

Novo Nordisk Buys $1bn Cardior in CardioVascular Move

As Novo Nordisk expands into heart medicines, we profile the Danish pharma giant who in 1923 was the first to make insulin commercially available

Shoddy Chinese Syringes Sees BD Ramp-up Production

Procurement & Supply Chain

AI Tool 'Picks up Early-stage Breast Cancers Doctors Missed'

Technology & AI

AstraZeneca Buys $2bn Fusion in Next-gen Cancer Drugs Move

Medical Devices & Pharma